Kura Oncology, Inc.
KURA
$9.22
-$0.52-5.34%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/13/2026
-
MarketBeat
5/15/2026
-
Simply Wall St
5/15/2026
-
MarketBeat
5/14/2026
-
TipRanks Financial Blog
5/14/2026
-
SeekingAlpha
5/14/2026
-
Seeking Alpha: Transcripts
5/13/2026
-
TipRanks Financial Blog
5/13/2026
-
TipRanks Financial Blog
5/13/2026
-
TipRanks Financial Blog
5/13/2026
-
SeekingAlpha
5/13/2026
-
Seeking Alpha: Transcripts
5/12/2026
-
Zacks Investment Research
5/12/2026
-
Zacks Investment Research
5/12/2026
-
Globe Newswire
5/12/2026
-
Globe Newswire
5/11/2026
-
Seeking Alpha - Healthcare
5/10/2026
-
MarketBeat
5/8/2026
-
MarketBeat
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Tickeron - Stocks
5/6/2026
-
Globe Newswire
5/5/2026
-
Zacks Investment Research
5/5/2026
-
Zacks Investment Research
5/5/2026
-
Globe Newswire
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, May 12, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
858 500 8800
Address
4930 Directors Place
San Diego, CA 92121
San Diego, CA 92121
Country
Year Founded
--
Business Description
Sector
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent...
more